IMCD reports 12% EBITA growth in the first nine months of 2019
12 Novembro 2019 - 03:00AM
IMCD reports 12% EBITA growth in the first nine months of 2019
Rotterdam, The Netherlands (12 November 2019)
- IMCD N.V. (“IMCD” or “Company”), a
leading distributor of speciality chemicals and food
ingredients, today announces its first nine months
2019 results.
Highlights
- Gross profit growth of 15% to EUR 457.3 million (+14% on a
constant currency basis)
- Operating EBITA increase of 12% to EUR 175.7 million (+11% on a
constant currency basis)
- Net result before amortisation and non-recurring items increase
of 10% to EUR 120.1 million (+9% on a constant currency basis)
- Cash earnings per share increased by 15% to EUR 2.26
- 30 August, acquisition of the food ingredients business of
Matrix (Singapore and Malaysia) and 18 September acquisition of
Monachem and Addpol, expanding IMCD's position in the Advanced
Materials industry in India
- Strengthening of pharma activities by signing agreements to
acquire the shares of DCS Pharma AG (Switzerland) and 57% of the
shares of Whawon Pharm Co. Ltd. (South Korea)
Piet van der Slikke, CEO: "The first nine months resulted in an
EBITA growth of 12% and a cash earnings per share growth of 15%
versus the same period of last year. Both the Americas and
Asia-Pacific performed satisfactorily whereas EMEA ‘s results were
disappointing (EBITA -2%) caused by lower demand. Despite this, we
are confident that we will continue to achieve our medium term
targets on organic growth and we are positive about the
acquisitions we have completed so far (Monachem and Matrix) and
those we expect to complete this year (DCS, Switzerland and Whawon,
South Korea)."
Please find attached the full press release.
- PRESS RELEASE_IMCD First nine months 2019 results
IMCD NV (EU:IMCD)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
IMCD NV (EU:IMCD)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024